mAbxience | Pipeline: in constant progression
in constant progression
At mAbxience we are working to increase patient access to high quality medicines.
Highly attractive pipeline targeting the areas of oncology, hematology osteoporosis and pediatrics.
mAbxience develops biosimilars and biopharmaceutical products adhering to a strict “quality by design” standard, using the latest innovations in upstream, downstream and cutting edge-analytics.
Biosimilars are equivalent in terms of quality, safety and efficacy to the reference products. mAbxience guarantees the equivalence by subjecting the drugs to exhaustive comparability testing, regulated by the competent authorities. This ensures that our biosimilars are as similar as possible to the reference product with respect to structure, biological activity and overall performance of the final drug product.
In addition, clinical trials are conducted in accordance to the regulatory requirements, to establish similar clinical performance of the product development.